Skip to main content
0

Head Genetics is a biotech company established to develop saliva-based concussion assessment device.

Head Genetics is outfitted with various assays that can detect biomarkers in a multitude of health conditions, initially targeting Concussion.

Saliva-based assessments garnered a lot of attention during the most recent pandemic. As mentioned, multiple times in the media.

EASY TO USE & NON-INVASIVE
Exceeds current concussion diagnostic protocol by bringing results closer to the individual.

INEXPENSIVE & FAST
Results obtained without expensive, lab or hospital-based equipment allowing individuals, clinicians and other healthcare providers to make virtual real time decisions.

PROJECT
Concussion Assessment Device

PROJECT STARTED
2013

MATERIALS
BPA Free, FDA approved, premium materials 

Head trauma happens everyday to millions

Millions of brain-related injuries contribute to an unknown number of future diseases, yet we have no way to measure for definitive trauma or qualify the trauma experienced.

WORLDWIDE STATISTICS
The TBI injury diagnostic global market is approaching $1.75 billion & is expected to reach $3 billion by 2028.

70

million cases of concussion annually

40

of concussive events remain undiagnosed

The current protocol for assessing brain trauma is indeterminate and slow. That ends now.

The problem

Brain-related injuries contribute to an unknown number of future diseases, yet we have no way to measure for definitive trauma or qualify the trauma experienced

Concussion

Head Genetics saliva-based over the counter (OTC) assay device will be a game changer for the at home user and clinicians knowing that the leading cause of mTBI is caused by falling. 

“the public is holding professional leagues accountable”

Recent viral media of player injuries have fans and viewers calling for complete protocol overhauls

Executive Team

FABIAN McLAREN

CEO + CO-FOUNDER

Fabian Maclaren is a biotech, pharmaceutical and personal care executive with 17 years experience in the development, branding, marketing and scale up of successful brands through the largest retailers in the United States and abroad. Multiple successful exits, 4 yr old brand exited at $500m, Proven international market share, $700m international through 50+ partners, Vital retail relationships, $300m wholesale domestic, Engaged influencer networks and activations, 20+ online partners, Consumer database of > 250 million contacts

GEORGE GALLO

CMO + CO-FOUNDER

George brings 20 years of visionary branding, packaging, digital marketing and e-commerce. He meticulously brings products to life through immaculate and cutting-edge design that inspires. Driven by passion and innovation, George Gallo, Founder of his award-winning agency The George Gallo Company, has developed impeccable products for an arsenal of globally recognized brands including LVMH, Target, Fendi & Westfield and more. He is guided by a vision to push the boundaries of creativity and fuse technology and design. He is lead the designer of the Taj brand and bottle design.

YAN WANG, PH.D., MBA

CHIEF TECHNOLOGY OFFICER

Ph.D. in Organic Chemistry and MBA from University of Wisconsin, Madison, 25 years of C-level experience and key management positions in pharmaceutical. During his time as President at SPL (Scientific Protein Laboratories LLC), Yan led the company to triple net income. Played a pivotal role in multiple rounds of M&A and “change of control” transactions totaling over $1Billion

PAUL SLOWEY, PH.D.

CHIEF SCIENCE OFFICER

Ph.D. in Organic Chemistry from the University of Newcastle-Upon-Tyne, UK and a Postdoctoral Fellowship at the University of Victoria, BC, Canada. He has over 35 years of experience in the clinical diagnostic and pharmaceutical industries combined during of which he has held C-level positions. Dr. Slowey has 45 publications in peer-reviewed journals, including seven published book chapters, seventeen (17) issued patents, ten (10) filed patent applications. Has made a number of oral presentations at key scientific symposia on a variety of subjects including HIV diagnosis, liquid biopsy testing for cancer diagnosis, nucleic acid testing, the status of oral fluid testing, the Japanese Healthcare Business and Thyrotropin Receptor Antibody Assays for the Diagnosis of Graves’ Disease.

Dr. BALWANT RAI

INVENTOR

Over 35 patents globally and contributed to multiple scientific studies and journals over the past 15 years. His work as a reviewer for the National Research Foundation of South Africa and NASA’s Post-Doctoral Program has earned him critical acclaim among the science community and contributed to him being a leader in the saliva diagnostics and medical devices field
Received his BDS from PT Bhagwat Dayal Sharma (PTBDS) Post Graduate Institute of Medical Sciences, a leading government medical institution. While at PTBDS, Dr. Rai completed residency in Critical Care Medicine, Medical Diagnostics, Biotechnology and Lab-Based Medicine. Dr. Rai also received his MS from Catholic University, Belgium.